Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to TreatmentPRECEPT

- Diagnosis of metastatic adenocarcinoma of the colon or rectum - Available paraffin-embedded tumor tissue - Failure of first line treatment containing fluoropyrimidine and oxaliplatin based chemotherapy with bevacizumab for mCRC - Measurable disease - Adequate hematologic, renal, hepatic and metabolic function

- Radiotherapy ≤ 2 weeks prior to Day 1 of Cycle 1 - Unresolved toxicity(ies) from prior anti cancer therapy that, in the opinion of the investigator, precludes the subject from study enrollment - Prior irinotecan therapy, anti epidermal growth factor receptor (EGFr) therapy, or vaccine for the treatment of mCRC - CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital, carbamazepine, ketoconazole, rifampin, rifabutin, and St. John’s Wort) ≤ 2 weeks prior to Day 1 of Cycle 1 - Infection requiring systemic anti infectives completed ≤ 2 weeks prior to Day 1 of Cycle 1 - Clinically significant cardiovascular disease - History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) - Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤ 8 weeks prior to Day 1 of Cycle 1 - Any significant bleeding ≤ 6 weeks prior to Day 1 of Cycle 1, per the investigator’s judgement - Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled gastrointestinal ulcer ≤ 4 weeks prior to Day1 of Cycle 1 - Any co-morbid disease or condition that could increase the risk of toxicity (eg, dihydropyrimidine deficiency, significant ascites, or pleural effusion) - Major surgery (requiring general anesthesia), open biopsy, or significant traumatic injury ≤ 4 weeks prior to Day1 of Cycle 1. Subjects must have recovered from surgery and have no significant complications